中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月8日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (25): 9-12    
  论著 本期目录 | 过刊浏览 | 高级检索 |
磁共振动态增强扫描联合扩散加权成像诊断子宫肉瘤的临床价值
周花
江西省赣州市妇幼保健院放射影像科,江西赣州 341000
Clinical value of dynamic contrast-enhanced magnetic resonance imaging combined with diffusion weighted imaging in the diagnosis of uterine sarcoma
ZHOU Hua
Department of Radiology, Ganzhou Maternal and Child Health Hospital, Jiangxi Province, Ganzhou 341000, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨磁共振动态增强扫描(DCE-MRI)联合扩散加权成像(DWI-MRI)诊断子宫肉瘤的临床价值。方法 回顾性分析2014年6月至2021年12月赣州市妇幼保健院的26例子宫肉瘤患者的临床资料,另选取赣州市妇幼保健院同期29例变性子宫肌瘤患者的临床资料展开分析,所有患者术前均接受常规彩超、DCE-MRI、DWIMRI检查诊断。比较子宫肉瘤与变性子宫肌瘤患者的最大对比增强率(MCER)、表观弥散系数(ADC)、达峰时间(TTP),以病理检查为金标准分析常规彩超、DCE-MRI联合DWI-MRI诊断子宫肉瘤的效能。结果 子宫肉瘤患者的MCER高于变性子宫肌瘤患者,TTP短于变性子宫肌瘤患者,ADC低于变性子宫肌瘤患者,差异有统计学意义(P<0.05)。常规彩超诊断子宫肉瘤的符合率为70.91%(39/55)、灵敏度为61.54%(16/26)、特异度为79.31%(23/29);MRI(DCE联合DWI)诊断子宫肉瘤的符合率为78.18%(43/55)、灵敏度为80.77%(21/26)、特异度为75.86%(22/29);受试者工作特征(ROC)曲线显示,MRI(95%CI=0.845~0.926,AUC=0.911)诊断子宫肉瘤的效能高于常规彩超(95% CI=0.881~0.927,AUC=0.898)。结论 DCE-MRI联合DWI-MRI诊断子宫肉瘤的敏感性好、符合率高,可为子宫肉瘤的术前无创诊断提供科学参考依据。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
周花
关键词 磁共振成像子宫肉瘤动态增强扫描扩散加权成像    
Abstract:Objective To investigate the clinical value of dynamic enhanced magnetic resonance (DCE-MRI) combined with diffusion-weighted imaging (DWI-MRI) in the diagnosis of uterine sarcoma. Methods The clinical data of 26 patients with uterine sarcoma in Ganzhou Maternal and Child Health Hospital from June 2014 to December 2021 were retrospectively analyzed, and the clinical data of 29 patients with degenerative uterine fibroids in Ganzhou Maternal and Child Health Hospital during the same period were selected for analysis. All patients were diagnosed by conventional color ultrasound, DCE-MRI and DWI-MRI before surgery. The maximum contrast enhancement rate (MCER), apparent dispersion coefficient (ADC) and peak time (TTP) of patients with uterine sarcoma and degenerative uterine fibroids were compared, and the efficacy of conventional color ultrasound, DCE-MRI combined with DWI-MRI in the diagnosis of uterine sarcoma was analyzed using pathological examination as the gold standard. Results The MCER of patients with uterine sarcoma was higher than that of patients with degenerative uterine fibroids, TTP was shorter than that of patients with degenerative uterine fibroids, ADC was lower than that of patients with degenerative uterine fibroids, and the differences were statistically significant (P<0.05). The coincidence rate, sensitivity and specificity of conventional color ultrasonography in the diagnosis of uterine sarcoma were 70.91% (39/55), 61.54% (16/26) and 79.31% (23/29), respectively. The coincidence rate, sensitivity and specificity of MRI (DCE combined with DWI) in the diagnosis of uterine sarcoma were 78.18% (43/55), 80.77% (21/26) and 75.86% (22/29), respectively. The receiver operating characteristic (ROC) curve showed that MRI (95%CI=0.845-0.926, AUC=0.911) in the diagnosis of uterine sarcoma was higher than conventional color ultrasound (95%CI=0.881-0.927, AUC=0.898). Conclusion DCE-MRI combined with DWI-MRI has good sensitivity and high coincidence rate in the diagnosis of uterine sarcoma, which can provide scientific reference for the preoperative non-invasive diagnosis of uterine sarcoma.
Key wordsMagnetic resonance imaging    Uterine sarcoma    Dynamic enhanced scanning    Diffusion-weighted imaging
    
基金资助:江西省赣州市科技计划项目(GZ2021ZSF306)
引用本文:   
周花. 磁共振动态增强扫描联合扩散加权成像诊断子宫肉瘤的临床价值[J]. 中国当代医药, 2022, 29(25): 9-12.
ZHOU Hua. Clinical value of dynamic contrast-enhanced magnetic resonance imaging combined with diffusion weighted imaging in the diagnosis of uterine sarcoma. 中国当代医药, 2022, 29(25): 9-12.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I25/9
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载